This Under-the-Radar Dementia Treatment Could Reward Investors

·5-min read
This Under-the-Radar Dementia Treatment Could Reward Investors

While the fall may partially be due to a secondary offering this June, it may also be due to underwhelming results in one of three potential indications for its lead compound, BXCL-501. Fortunately, its two other indications are showing promising results, and the company may be poised to rebound. BioXcel's lead compound is a dissolving oral film of dexmedetomidine, a drug that has been around for a while.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting